{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:27:58Z","timestamp":1788560878086,"version":"build-2803163510"},"reference-count":109,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008222","name":"Ben and Catherine Ivy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008222","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA227156-01"],"award-info":[{"award-number":["1R01CA227156-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA244975-01"],"award-info":[{"award-number":["1R01CA244975-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Brain metastases account for considerable morbidity and mortality in patients with cancer. Despite increasing prevalence, limited therapeutic options exist. Recent advances in our understanding of the molecular and cellular underpinnings of the tumor immune microenvironment and the immune evasive mechanisms employed by tumor cells have shed light on how immunotherapies may provide therapeutic benefit to patients. The development and evolution of immunotherapy continue to show promise for the treatment of brain metastases. Positive outcomes have been observed in several studies evaluating the efficacy and safety of these treatments. However, many challenges persist in the application of immunotherapies to brain metastases. This review discusses the potential benefits and challenges in the development and use of checkpoint inhibitors, chimeric antigen receptor T-cell therapy, and oncolytic viruses for the treatment of brain metastases. Future studies are necessary to further evaluate and assess the potential use of each of these therapies in this setting. As we gain more knowledge regarding the role immunotherapies may play in the treatment of brain metastases, it is important to consider how these treatments may guide clinical decision making for clinicians and the impact they may have on patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Immunotherapies have produced clinically significant outcomes in early clinical trials evaluating patients with brain metastases or demonstrated promising results in preclinical models. Checkpoint inhibitors have been the most common immunotherapy studied to date in the setting of brain metastases, but novel approaches that can harness the immune system to contain and eliminate cancer cells are currently under investigation and may soon become more common in the clinical setting. An understanding of these evolving therapies may be useful in determining how the future management and treatment of brain metastases among patients with cancer will continue to advance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/onco.13575","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T08:37:04Z","timestamp":1603701424000},"page":"231-241","source":"Crossref","is-referenced-by-count":45,"title":["Emerging Immunotherapies in the Treatment of Brain Metastases"],"prefix":"10.1093","volume":"26","author":[{"given":"Edwin","family":"Nieblas-Bedolla","sequence":"first","affiliation":[{"name":"University of Washington School of Medicine, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naema","family":"Nayyar","sequence":"additional","affiliation":[{"name":"Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA"},{"name":"Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, Massachusetts, USA"},{"name":"Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohini","family":"Singh","sequence":"additional","affiliation":[{"name":"Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Division of Hematology\/Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachustets, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla K.","family":"Brastianos","sequence":"additional","affiliation":[{"name":"Broad Institute of Massachusetts Institute of Technology and Harvard, Boston, Massachusetts, USA"},{"name":"Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Division of Hematology\/Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachustets, USA"},{"name":"Division of Neuro-Oncology, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachustets, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"2021122512035752700_onco13575-bib-0001","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02782192","article-title":"Long-term survival with metastatic cancer to the brain","volume":"17","author":"Hall","year":"2000","journal-title":"Med Oncol"},{"key":"2021122512035752700_onco13575-bib-0002","article-title":"Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole-brain radiation therapy","volume":"19","author":"McTyre","year":"2016","journal-title":"Neuro Oncol"},{"key":"2021122512035752700_onco13575-bib-0003","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.wneu.2013.02.025","article-title":"Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases","volume":"82","author":"Neal","year":"2014","journal-title":"World Neurosurg"},{"key":"2021122512035752700_onco13575-bib-0004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3747\/co.v15i5.290","article-title":"Quality of life in brain metastases radiation trials: A literature review","volume":"15","author":"Wong","year":"2008","journal-title":"Curr Oncol"},{"key":"2021122512035752700_onco13575-bib-0005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","article-title":"Epidemiology of brain metastases","volume":"14","author":"Nayak","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"2021122512035752700_onco13575-bib-0006","first-page":"4655","article-title":"Recent trends in epidemiology of brain metastases: An overview","volume":"32","author":"Tabouret","year":"2012","journal-title":"Anticancer Res"},{"key":"2021122512035752700_onco13575-bib-0007","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122512035752700_onco13575-bib-0008","first-page":"2349","article-title":"Central nervous system metastasis from breast carcinoma","volume":"52","author":"Tsukada","year":"1983","journal-title":"Autopsy study. Cancer"},{"key":"2021122512035752700_onco13575-bib-0009","first-page":"579","article-title":"Intracranial metastases from systemic cancer","volume":"19","author":"Posner","year":"1978","journal-title":"Adv Neurol"},{"key":"2021122512035752700_onco13575-bib-0010","first-page":"398","article-title":"Neoplasms of the central nervous system: Epidemiologic considerations","volume":"20","author":"Percy","year":"1970","journal-title":"Neurology"},{"key":"2021122512035752700_onco13575-bib-0011","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ctrv.2004.05.001","article-title":"The treatment of brain metastases in melanoma patients","volume":"30","author":"Bafaloukos","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"2021122512035752700_onco13575-bib-0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"2021122512035752700_onco13575-bib-0013","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/cncr.25707","article-title":"Presentation, patterns of care, and survival in patients with brain metastases","volume":"117","author":"Nieder","year":"2011","journal-title":"Cancer"},{"key":"2021122512035752700_onco13575-bib-0014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2014.25","article-title":"Current approaches to the treatment of metastatic brain tumours","volume":"11","author":"Owonikoko","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122512035752700_onco13575-bib-0015","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fonc.2016.00049","article-title":"Systemic immunotherapy for the treatment of brain metastases","volume":"6","author":"Cohen","year":"2016","journal-title":"Front Oncol"},{"key":"2021122512035752700_onco13575-bib-0016","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122512035752700_onco13575-bib-0017","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2021122512035752700_onco13575-bib-0018","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0019","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"2021122512035752700_onco13575-bib-0020","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122512035752700_onco13575-bib-0021","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"2021122512035752700_onco13575-bib-0022","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"2021122512035752700_onco13575-bib-0023","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 15","key":"2021122512035752700_onco13575-bib-0024","doi-asserted-by":"crossref","first-page":"8035a","DOI":"10.1200\/jco.2015.33.15_suppl.8035","article-title":"Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases","volume":"33","author":"Goldberg","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122512035752700_onco13575-bib-0025","doi-asserted-by":"crossref","first-page":"9009a","DOI":"10.1200\/jco.2015.33.15_suppl.9009","article-title":"Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases","volume":"33","author":"Kluger","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122512035752700_onco13575-bib-0026","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: Long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"2021122512035752700_onco13575-bib-0027","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","article-title":"Non\u2013small-cell lung cancer with brain metastasis at presentation","volume":"19","author":"Waqar","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"2021122512035752700_onco13575-bib-0028","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: Recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"2021122512035752700_onco13575-bib-0029","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"2021122512035752700_onco13575-bib-0030","article-title":"A century of radiation therapy and adaptive immunity","volume":"8431","author":"Schaue","year":"2017","journal-title":"Front Immunol"},{"key":"2021122512035752700_onco13575-bib-0031","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fonc.2019.00163","article-title":"Turning \u2018cold\u2019 into \u2018hot\u2019 tumors - Opportunities and challenges for radio-immunotherapy against primary and metastatic brain cancers","volume":"9","author":"Sevenich","year":"2019","journal-title":"Front Oncol"},{"key":"2021122512035752700_onco13575-bib-0032","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PPO.0000000000000327","article-title":"Combinations of bevacizumab with cancer immunotherapy","volume":"24","author":"Chen","year":"2018","journal-title":"Cancer J"},{"key":"2021122512035752700_onco13575-bib-0033","article-title":"Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors","volume":"101023","author":"De Aguiar","year":"2019","journal-title":"Front Immunol"},{"key":"2021122512035752700_onco13575-bib-0034","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2021122512035752700_onco13575-bib-0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"2021122512035752700_onco13575-bib-0036","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2018-0306","article-title":"Upfront surgical resection of melanoma brain metastases provides a bridge toward immunotherapy-mediated systemic control","volume":"24","author":"Alvarez-Breckenridge","year":"2019","journal-title":"The Oncologist"},{"key":"2021122512035752700_onco13575-bib-0037","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"2021122512035752700_onco13575-bib-0038","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"2021122512035752700_onco13575-bib-0039","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0040","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2021122512035752700_onco13575-bib-0041","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0042","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.cell.2018.03.026","article-title":"Cancer-germline antigen expression discriminates clinical outcome to CTLA-4 blockade","volume":"173","author":"Shukla","year":"2018","journal-title":"Cell"},{"key":"2021122512035752700_onco13575-bib-0043","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nrd.2016.233","article-title":"Dynamic versus static biomarkers in cancer immune checkpoint blockade: Unravelling complexity","volume":"16","author":"Lesterhuis","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2021122512035752700_onco13575-bib-0044","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3389\/fimmu.2018.01474","article-title":"Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-A review from the melanoma perspective and beyond","volume":"9","author":"Buder-Bakhaya","year":"2018","journal-title":"Front Immunol"},{"key":"2021122512035752700_onco13575-bib-0045","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2021122512035752700_onco13575-bib-0046","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2021122512035752700_onco13575-bib-0047","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"2021122512035752700_onco13575-bib-0048","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets genetic divergence of brain metastases and primary tumors","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"key":"2021122512035752700_onco13575-bib-0049","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","article-title":"Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab","volume":"24","author":"Joseph","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2021122512035752700_onco13575-bib-0050","doi-asserted-by":"crossref","first-page":"815","DOI":"10.21873\/anticanres.13180","article-title":"Baseline tumor size as a predictive and prognostic factor of immune checkpoint inhibitor therapy for non-small cell lung cancer","volume":"39","author":"Katsurada","year":"2019","journal-title":"Anticancer Res"},{"key":"2021122512035752700_onco13575-bib-0051","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0052","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PPO.0000000000000296","article-title":"Toxicities associated with PD-1\/PD-L1 blockade","volume":"24","author":"Wang","year":"2018","journal-title":"Cancer J"},{"key":"2021122512035752700_onco13575-bib-0053","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0054","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0056","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0057","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","article-title":"Inflammatory CNS disease caused by immune checkpoint inhibitors: Status and perspectives","volume":"13","author":"Yshii","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"2021122512035752700_onco13575-bib-0058","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.3389\/fimmu.2018.02593","article-title":"Making CAR T cells a solid option for solid tumors","volume":"9","author":"Schmidts","year":"2018","journal-title":"Front Immunol"},{"key":"2021122512035752700_onco13575-bib-0059","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3389\/fimmu.2018.02486","article-title":"Expanding the therapeutic window for CAR T cell therapy in solid tumors: The knowns and unknowns of CAR T cell biology","volume":"9","author":"Watanabe","year":"2018","journal-title":"Front Immunol"},{"key":"2021122512035752700_onco13575-bib-0060","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122512035752700_onco13575-bib-0061","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122512035752700_onco13575-bib-0062","volume-title":"Press release","author":"FDA approval brings first gene therapy to the United States","year":"2017"},{"key":"2021122512035752700_onco13575-bib-0063","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"2021122512035752700_onco13575-bib-0064","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"2021122512035752700_onco13575-bib-0065","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"2021122512035752700_onco13575-bib-0066","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0067","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"2021122512035752700_onco13575-bib-0068","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) \u2013specific chimeric antigen receptor\u2013modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122512035752700_onco13575-bib-0069","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J Clin Invest"},{"key":"2021122512035752700_onco13575-bib-0070","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","article-title":"Universal chimeric antigen receptors for multiplexed and logical control of T cell responses","volume":"173","author":"Cho","year":"2018","journal-title":"Cell"},{"key":"2021122512035752700_onco13575-bib-0071","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"2021122512035752700_onco13575-bib-0072","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"2021122512035752700_onco13575-bib-0073","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0074","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13R 2-redirected chimeric antigen receptor CD8+ T Cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122512035752700_onco13575-bib-0075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor\u2013engineered T cells effectively targets HER2 + breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2021122512035752700_onco13575-bib-0076","doi-asserted-by":"crossref","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"2021122512035752700_onco13575-bib-0077","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"2021122512035752700_onco13575-bib-0078","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: The promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2021122512035752700_onco13575-bib-0079","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"2021122512035752700_onco13575-bib-0080","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"2021122512035752700_onco13575-bib-0081","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41577-019-0200-1","article-title":"Engineering universal cells that evade immune detection","volume":"19","author":"Lanza","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"2021122512035752700_onco13575-bib-0082","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2021122512035752700_onco13575-bib-0083","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3389\/fimmu.2018.01740","article-title":"CAR T cells in solid tumors: Blueprints for building effective therapies","volume":"9","author":"Knochelmann","year":"2018","journal-title":"Front Immunol"},{"key":"2021122512035752700_onco13575-bib-0084","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T-cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"key":"2021122512035752700_onco13575-bib-0085","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4220","article-title":"Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen\u2013specific CTLs","volume":"9","author":"Brown","year":"2017","journal-title":"Sci Transl Med"},{"key":"2021122512035752700_onco13575-bib-0086","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/neuonc\/noy075","article-title":"Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC","volume":"20","author":"Cloughesy","year":"2018","journal-title":"Neuro Oncol"},{"key":"2021122512035752700_onco13575-bib-0087","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1038\/s41467-018-07344-1","article-title":"PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance","volume":"9","author":"Russell","year":"2018","journal-title":"Nat Commun"},{"key":"2021122512035752700_onco13575-bib-0088","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models","volume":"10","author":"Mart\u00ednez-V\u00e9lez","year":"2019","journal-title":"Nat Commun"},{"key":"2021122512035752700_onco13575-bib-0089","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s12094-012-0951-7","article-title":"Viruses in cancer treatment","volume":"15","author":"Alemany","year":"2013","journal-title":"Clin Transl Oncol"},{"key":"2021122512035752700_onco13575-bib-0090","volume-title":"U.S. Food and Drug Administration Web site","author":"IMLYGIC (talimogene laherparepvec)"},{"key":"2021122512035752700_onco13575-bib-0091","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2021122512035752700_onco13575-bib-0092","doi-asserted-by":"crossref","first-page":"e1003836","DOI":"10.1371\/journal.ppat.1003836","article-title":"From scourge to cure: Tumour-selective viral pathogenesis as a new strategy against cancer","volume":"10","author":"Ilkow","year":"2014","journal-title":"PLoS Pathog"},{"key":"2021122512035752700_onco13575-bib-0093","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/mt.2014.21","article-title":"Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults","volume":"22","author":"Kicielinski","year":"2014","journal-title":"Mol Ther"},{"key":"2021122512035752700_onco13575-bib-0094","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/sj.mt.6300403","article-title":"A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas","volume":"16","author":"Forsyth","year":"2018","journal-title":"Mol Ther"},{"key":"2021122512035752700_onco13575-bib-0095","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0096","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade","volume":"10","author":"Samson","year":"2018","journal-title":"Sci Transl Med"},{"key":"2021122512035752700_onco13575-bib-0097","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ymthe.2005.03.026","article-title":"HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer","volume":"12","author":"Benencia","year":"2005","journal-title":"Mol Ther"},{"key":"2021122512035752700_onco13575-bib-0098","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122512035752700_onco13575-bib-0099","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122512035752700_onco13575-bib-0100","doi-asserted-by":"crossref","first-page":"e000253","DOI":"10.1136\/esmoopen-2017-000253","article-title":"Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases","volume":"2","author":"Siravegna","year":"2017","journal-title":"ESMO Open"},{"key":"2021122512035752700_onco13575-bib-0101","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0102","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat Commun"},{"key":"2021122512035752700_onco13575-bib-0103","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122512035752700_onco13575-bib-0104","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"2021122512035752700_onco13575-bib-0105","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","article-title":"Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): Results from a phase 3, non-inferiority, randomised trial","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet"},{"key":"2021122512035752700_onco13575-bib-0106","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.seizure.2011.12.016","article-title":"The pathogenesis of tumor-related epilepsy and its implications for clinical treatment","volume":"21","author":"You","year":"2012","journal-title":"Seizure"},{"key":"2021122512035752700_onco13575-bib-0107","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11060-009-0056-5","article-title":"The role of prophylactic anticonvulsants in the management of brain metastases: A systematic review and evidence-based clinical practice guideline","volume":"96","author":"Mikkelsen","year":"2010","journal-title":"J Neurooncol"},{"key":"2021122512035752700_onco13575-bib-0108","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10143-018-1013-6","article-title":"Neurosurgical management of patients with brain metastasis","volume":"43","author":"Hatiboglu","year":"2020","journal-title":"Neurosurg Rev"},{"key":"2021122512035752700_onco13575-bib-0109","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cell.2017.02.025","article-title":"Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis","volume":"168","author":"Boire","year":"2017","journal-title":"Cell"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13575","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13575","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/3\/231\/41923608\/oncolo_26_3_231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/3\/231\/41923608\/oncolo_26_3_231.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:04:52Z","timestamp":1640415892000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/3\/231\/6445520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":109,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,11,10]]},"published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13575","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,11,10]]}}}